Evoke Wealth’s Ocular Therapeutix OCUL Stock Holding History

Evoke Wealth’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,323	Closed	-$69K	–	1193
2020 Q4	$69K	Buy	+3,323	New	+$49.4K	﹤0.01%	335

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Evoke Wealth's OCUL Position: Q1 2021 in Review

Evoke Wealth sold out of Ocular Therapeutix (OCUL) in Q1 2021, closing a stake of 3,323 shares — an estimated $69K sold.

Evoke Wealth first reported a position in OCUL in Q4 2020 and held it in 1 quarter. The position peaked at $69K in Q4 2020. 154 funds tracked by Wall St. Rank hold OCUL as of Q1 2021.

Evoke Wealth reported no remaining Ocular Therapeutix position as of Q1 2021 after selling out during the quarter.
Evoke Wealth sold 3,323 Ocular Therapeutix shares in Q1 2021, an estimated $69K.
Evoke Wealth first reported a position in Ocular Therapeutix in Q4 2020 and held it in 1 quarter.
Evoke Wealth's Ocular Therapeutix position peaked at $69K in Q4 2020.
154 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2021.

Based on Evoke Wealth's 13F filing for Q1 2021, filed 13 May 2021.